Table 2.
Type of anti-HER2 treatment received in the neoadjuvant and adjuvant settings prior to neratinib
| Setting (n/N, %) | Type of anti-HER2 | n (%) |
|---|---|---|
| Neoadjuvant (151/187, 80.7%) | Trastuzumab + pertuzumab | 127 (84.1) |
| Trastuzumab | 10 (6.6) | |
| Pertuzumab | 2 (1.3) | |
| No anti-HER2 | 12 (7.9) | |
| Post-neoadjuvant (151/187, 80.7%)a,b | ||
| After pCR (82/151, 54.3%) | Trastuzumab | 46 (56.1) |
| Trastuzumab + pertuzumab | 32 (39.0) | |
| Other anti-HER2c | 2 (2.4) | |
| Not yet documented | 2 (2.4) | |
| After non-pCR (67/151, 44.4%) | Trastuzumab | 7 (10.4) |
| Trastuzumab + pertuzumab | 17 (25.4) | |
| T-DM1 | 36 (53.7) | |
| Other anti-HER2 | 6 (9.0) | |
| Not yet documented | 1 (1.5) | |
| Adjuvant (no prior neoadjuvant) (36/187, 19.3%) | Trastuzumab | 24 (66.7) |
| Trastuzumab + pertuzumab | 12 (33.3) | |
HER2, human epidermal growth factor receptor 2; pCR, pathological complete response; T-DM1, trastuzumab emtansine.
aThe post-neoadjuvant treatment was not documented for 4 patients.
bpCR status was unknown in 2 patients.
c“Other anti-HER2 treatments” included other combinations and/or sequences of trastuzumab, pertuzumab, and/or T-DM1.